Dosing & Uses
Allogeneic Hematopoietic Stem Cell Transplantation
Pending FDA approval for patients with blood cancers in need of an allogenic hematopoietic stem cell transplant
Next:
Pharmacology
Mechanism of Action
Omidubicel consists of ex vivo-expanded umbilical cord blood-derived allogeneic hematopoietic CD34-positive progenitor cells (HCPs)
Can be used during transplantation; these cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells
Compared to bone marrow transplants, these HPCs have decreased risk of causing graft-versus host disease (GvHD), increased survival, and enhanced transplant and engraftment potential for any given patient as there is no need for a matched donor
Previous
Next:
Images
Pricing & Images are not currently available for this monograph.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
